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Abstract
Background: Activation of the renin-angiotensin-aldosterone-system (RAAS) has been proposed to contribute to
development of vascular complications in type 2 diabetes (T2D). The aim of the present study was to determine if
plasma renin levels are associated with the severity of vascular changes in subjects with and without T2D.
Methods: Renin was analyzed by the Proximity Extension Assay in subjects with (n = 985) and without (n = 515)
T2D participating in the SUMMIT (SUrrogate markers for Micro- and Macro-vascular hard endpoints for Innovative
diabetes Tools) study and in 205 carotid endarterectomy patients. Vascular changes were assessed by determining
ankle-brachial pressure index (ABPI), carotid intima-media thickness (IMT), carotid plaque area, pulse wave velocity
(PWV) and the reactivity hyperemia index (RHI).
Results: Plasma renin was elevated in subjects with T2D and demonstrated risk factor-independent association
with prevalent cardiovascular disease both in subjects with and without T2D. Renin levels increased with age,
body mass index, HbA1c and correlated inversely with HDL. Subjects with T2D had more severe carotid disease,
increased arterial stiffness, and impaired endothelial function. Risk factor-independent associations between renin
and APBI, bulb IMT, carotid plaque area were observed in both T2D and non-T2D subjects. These associations
were independent of treatment with RAAS inhibitors. Only weak associations existed between plasma renin and
the expression of pro-inflammatory and fibrous components in plaques from 205 endarterectomy patients.
Conclusions: Our findings provide clinical evidence for associations between systemic RAAS activation and
atherosclerotic burden and suggest that this association is of particular importance in T2D.
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Background
Activation of the renin-angiotensin-aldosterone-system
(RAAS) has been implicated in the development of
vascular complications in type 2 diabetes (T2D) [1, 2].
Approximately 75 % of subjects with T2D have hyper-
tension [3]. Factors contributing to raising blood pressure
in T2D include elevated production of angiotensinogen in
abdominal fat and hyperinsulinemia-dependent activation
of the sympathetic nervous system stimulating renin ex-
pression [4, 5]. Renin is the key activator of RAAS [6, 7].
It is primarily produced by the juxtaglomerular apparatus
in the afferent arterioles of the kidney and functions by
hydrolyzing angiotensinogen into angiotensin I. Angioten-
sin I is subsequently cleaved by angiotensin-converting
enzyme (ACE) to generate angiotensin II, a powerful vaso-
constrictor that increases blood pressure [7]. However,
angiotensin II has also been reported to have several other
biological effects including stimulation of smooth muscle
cell proliferation and hypertrophy, oxidative stress, as well
as the release of pro-inflammatory cytokines and pro-
fibrotic factors that may contribute to the development of
macrovascular complications in diabetes also in other ways
beyond blood pressure [7–10]. Accordingly, blockade of
angiotensin II receptors attenuates the development of ath-
erosclerosis in apolipoprotein E knockout mice with
streptozotocin-induced diabetes [11, 12]. However, stimula-
tion of smooth muscle cell proliferation and extracellular
matrix synthesis may also help stabilize vulnerable athero-
sclerotic plaques [13] suggesting that activation RAAS may
have both detrimental and beneficial effects on cardiovas-
cular disease in T2D. Intervention studies using ACE inhib-
itors or angiotensin receptor blockers (ARBs) in patients
with diabetes have demonstrated a reduction of cardiovas-
cular events [14–16], but it remains to be fully understood
to what extent this involves effects on the vasculature that
are unrelated to the effects of RAAS on the blood pressure.
To further explore the relation between activation of
RAAS and vascular complications in diabetes we ana-
lyzed the association between plasma renin levels and
markers of atherosclerosis, arterial stiffness and endothe-
lial dysfunction in 1500 subjects with and without T2D
matched for age, gender and prevalence of CVD participat-
ing in the SUMMIT (SUrrogate markers for Micro- and
Macro-vascular hard endpoints for Innovative diabetes
Tools) study. Furthermore to determine if plasma levels
of renin were related with atherosclerotic plaque pheno-
type we analyzed their association with markers of inflam-
mation and fibrous components in 205 carotid plaques
obtained at endarterectomy.
Methods
Study populations
The SUrrogate markers for Micro- and Macro-vascular
hard endpoints for Innovative diabetes Tools (SUMMIT)
study cohort consisted of 4 groups; (1) subjects with T2D
and clinically manifest CVD, (2) subjects with T2D but
without clinical signs of CVD, (3) subjects with CVD but
no diabetes and (4) subjects without both CVD and dia-
betes recruited from existing population cohorts and
hospital registers at the university hospitals in Malmö
(Sweden), Pisa (Italy), Dundee and Exeter (UK) between
December 2010 and April 2013 [17]. Diabetes was de-
fined by current or previous evidence of hyperglycemia
(according to WHO 1998 criteria; fasting plasma glu-
cose >7.0 mmol/l or 2-h plasma glucose >11.1 mmol/l,
or both) or by current medication with insulin, sulphony-
lureas, metformin or other anti-diabetic drugs. A clinical
history of CVD included a previous diagnosis in the
clinical record of non-fatal acute myocardial infarction
(MI), hospitalized unstable angina, resuscitated cardiac
arrest, any coronary revascularization procedure, non-
fatal stroke, transient ischemic attack confirmed by a
specialist, lower extremities arterial disease defined as
Ankle Brachial Pressure Index (ABPI) <0.9 with intermit-
tent claudication or prior corrective surgery, angioplasty
or above ankle amputation. T2D with and without CVD
were matched at each center for gender, age (±5 years)
and duration of diabetes (±5 years). Subjects without
T2D were matched for gender and age (±5 years) at
each center. Subjects with CVD with or without T2D
were matched for CVD type. Exclusion criteria included
renal replacement therapy, malignancy requiring active
treatment, end-stage renal disease, any chronic inflam-
matory disease on therapy, previous bilateral carotid
artery invasive interventions or age <40 years. Demo-
graphics, clinical characteristics including medication,
physical and laboratory examinations were obtained ac-
cording to a pre-defined study protocol at all 4 partici-
pating centers.
Carotid ultrasound, endothelial function, arterial stiffness
and ankle brachial pressure index measurements
Carotid intima media thickness (IMT) was measured
both in common carotid artery (CCA) and in the bulb as
previously described [17]. To calculate carotid plaque
area the proximal-distal boundaries of a plaque were set
where the echo of the intima began to diverge from the
adventitia echo forming a focal thickening of the intima-
media-complex. The plaque area was assessed by outlining
the contours of the plaque using the trace function on the
ultrasound machine. The plaque area represents the sum
of all plaques detected in the carotid artery and the values
shown in this study represent the mean of the left and right
carotid arteries.
Endothelial function was measured using EndoPat
(Itamar Medical, Caesarea Ind. Park, Israel) to estimate
the endothelium-dependent vasodilation following post-
ischemic hyperemia [17].
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The reactive hyperemia index (RHI) was calculated as a
post-occlusion to pre-occlusion ratio of the signal ampli-
tudes. Thirty-one subjects were excluded from the RHI
analysis due to incomplete occlusion (brachial pulses from
the occluded arm were visible during occlusion, despite an
increase of the pressure of the cuff to the maximum level
of 300 mmHg) or time of occlusion was > or < 5 mins.
Arterial stiffness was assessed by calculating pulse wave
velocity (PWV) using a Sphygmocor device (Atcor Medical,
Australia). The carotid and femoral pulses were captured.
PWV (m/s) was automatically calculated as the measured
distance divided by the differences in time between the R
wave of the ECG to the foot of the carotid and femoral
pulse curves as previously described [17].
The ankle brachial pressure index (ABPI) was calculated
as the ratio between the highest systolic blood pressure
values from each foot respectively and the blood pressure
from the arm giving the highest value. Values given repre-
sent the mean of the left and right ABPI.
Carotid endarterectomy patients and analyses of plaque
tissue
Two hundred and five human carotid plaques were
collected at carotid endarterectomy. The indications for
surgery were plaques associated with ipsilateral symptoms
(transitory ischemic attack, stroke or amaurosis fugax) and
stenosis >70 % or plaques not associated with symptoms
and stenosis >80 %, measured by duplex. Patients were
preoperatively assessed by a neurologist. Blood samples
were collected one day before endarterectomy. Informed
consent was given by each patient. The study was approved
by the local ethical committee. Plaques were snap-frozen
in liquid nitrogen immediately after surgical removal.
Plaque homogenates were prepared as previously described
[18]. One mm fragments, from the most stenotic region,
were taken for histology. Stains for lipids (Oil Red O),
vascular smooth muscle cells (α-actin) and macrophages
(CD68) were performed as previously described [19].
Measurements of the area of plaque (% area) for the differ-
ent stainings were quantified blindly using BiopixiQ 2.1.8
(Gothenburg, Sweden) after scanning with ScanScope
Console Version 8.2 (LRI imaging AB, Vista CA, USA).
Finally aliquots of 50 μL of plaque homogenate were
centrifuged at 13,000 g for 10 min. Twenty-five μL of the
supernatant was removed and used for measuring differ-
ent cytokines and growth factors. The procedure was
performed according to the manufacturer’s instructions
(Human Cytokine/chemokine immunoassay, Millipore
Corporation, MA, USA) and analyzed with Luminex 100
IS 2.3 (Austin, Texas, USA). Elastin and collagen in plaque
homogenates were measured using the Fastin Elastin and
Sircol soluble Collagen assays as previously described [19].
Renin levels in plaque homogenates were analyzed using
the Proximity Extension Assay (see below).
Analysis of renin and IL-6 in plasma
Plasma levels of renin and IL-6 were analyzed by the
Proximity Extension Assay (PEA) technique using the
Proseek Multiplex CVD96×96 reagents kit (Olink Bioscience,
Uppsala, Sweden) at the Clinical Biomarkers Facility, Sci-
ence for Life Laboratory, Uppsala. Oligonucleotide-labeled
antibody probe pairs were allowed to bind to their re-
spective targets present in the plasma sample and addition
of a DNA polymerase led to an extension and joining of
the two oligonucleotides and formation of a PCR tem-
plate. Universal primers were used to pre-amplify the
DNA templates in parallel. Finally, the individual DNA se-
quences were detected and quantified using specific
primers by microfluidic real-time quantitative PCR chip
(96.96, Dynamic Array IFC, Fluidigm Biomark). The chip
was run with a Biomark HD instrument. The mean coeffi-
cients of variance for intra-assay variation and inter-assay
variation are 7 and 13 % for renin, and 8 and 10 % for
IL-6, respectively. All samples were analyzed in the
same run. Data analysis was performed by a preprocess-
ing normalization procedure using Olink Wizard for
GenEx (Multid Analyses, Sweden). All data are presented
as arbitrary units (AU). General calibrator curves to calcu-
late the approximate concentrations as well as technical
information about the assays are available on the Olink
homepage (http://www.olink.com).
Statistics
Statistical analyses were performed based on log2-
transformed renin levels to approximate normal distribu-
tion. Assessment of association with other markers was
done via Pearson correlation coefficient and linear regres-
sion models adjusted to study center and the individual
factors from the Framingham risk score (age, gender, total
cholesterol, HDL cholesterol, systolic blood pressure, and
smoking). Statistical significance of the association in the
linear regression model is judged by the p-value of the
renin coefficient.
For assessing associations of renin levels with CVD
risk logistic regression models were used, and adjust-
ment for factors of the Framingham risk score and study
center were done. Spearman correlations were used to
determine associations between plasma renin levels and
components of endarterectomy specimens. Statistical
analyses of the SUMMIT study were done using the R
version 3.1.1 and the IBM SPSS (version 22) software
was used for the carotid endarterectomy study.
Results
Plasma renin levels are increased in both T2D and
prevalent CVD
The design of the SUMMIT study has previously been re-
ported [17]. Briefly, this cross-sectional cohort involves
985 T2D subjects and 515 subjects without T2D matched
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for age, gender and prevalence of CVD recruited at four
different European academic health centers (Malmö,
Dundee, Exeter and Pisa). The clinical characteristics of
the study cohort are shown in Table 1. Plasma renin
levels were significantly higher in subjects with T2D
(median (IQR) 267 (157–458) versus 148 (98–260) AU
in non-T2D). Subjects with prevalent CVD had in-
creased levels of renin in both the T2D (333 (199–554)
versus 214 (128–365) AU and non-T2D groups (214
(128–333) versus 119 (87–176) AU, Fig. 1). To deter-
mine if the renin association with CVD was independ-
ent of major cardiovascular risk factors we adjusted for
the factors included in the Framingham risk score (e.g.
age, gender, total cholesterol, HDL, systolic blood pres-
sure and smoking) using logistic regression models.
The results demonstrated that high levels of renin were
independently associated with higher odds ratios for
CVD in both the T2D and non-T2D groups. The asso-
ciations with CVD remained significant when adjusting
for renal function (estimated glomerular filtration rate;
eGFR) and in the T2D also when adjusting for treat-
ment with RAAS inhibitors (Table 2).
Association between plasma renin and risk factors
The levels of renin in plasma increased with age, body
mass index (BMI), HbA1c and triglycerides, and showed
inverse associations with LDL cholesterol, HDL choles-
terol and renal function as assessed by the eGFR. Notably,
these associations were at least as strong in non-T2D
subjects as in the T2D group (Table 3). There was also
a significant association with inflammation as assessed
by plasma IL-6 levels in both groups. An inverse associ-
ation between renin and systolic blood pressure was ob-
served in the T2D group but not in the non-T2D group.
Association between plasma renin and measures of
atherosclerosis, arterial stiffness and endothelial function
We next analyzed if renin levels were related to the se-
verity of vascular changes. Peripheral artery disease was
determined by the ankle-brachial pressure index (ABPI),
carotid disease by the intima-media thickness (IMT) in
the common carotid artery (CCA) and the carotid bulb
as well as by carotid plaque area, arterial stiffness by
measuring pulse wave velocity (PWV) and endothelial
function by determining the Reactivity Hyperemia Index
Table 1 Clinical characteristics of the study cohort
T2D with CVD T2D without CVD Non-T2D without CVD Non-T2D with CVD
N 458 527 270 245
Male sex, n(%) 331 (72) 324 (61) 163 (60) 161 (66)
Age, years 69.3 (7.8) 66.2 (8.8) 66.4 (9.1) 67.9 (9.2)
T2D Duration, years 12.2 (8.8) 9.1 (6.9) – –
BMI, kg/m2 30.1 (4.9) 30.8 (5.5) 27.0 (4.0) 27.6 (4.1)
Medication
Statin use, n(%) 401 (88) 321 (61) 97 (36) 171 (70)
Anti-hypertensive treatment use, n(%) 419 (92) 352 (67) 129 (48) 172 (70)
Blood pressure
SBP, mmHg 138 (20.0) 136 (17.6) 132 (17.2) 134 (16.0)
DBP, mmHg 76 (10.3) 78 (9.8) 77 (9.4) 77 (9.2)
Pulse pressure, mmHg 62.6 (16.2) 58.2 (13.1) 54.5 (12.5) 57.2 (14.2)
Metabolic factors
HbA1c, mmol/mol
%
58.8 (13.9)
8.0 (5.0)
56.6 (13.0)
7.9 (10.0)
38.4 (3.9)
5.8 (2.3)
39.8 (4.7)
5.8 (0.5)
Tot Cholesterol, mmol/l 3.92 (0.9) 4.38 (1.0) 5.03 (1.1) 4.47 (1.1)
HDL, mmol/l 1.19 (0.35) 1.32 (0.38) 1.51 (0.44) 1.42 (0.40)
LDL, mmol/l 2.06 (0.74) 2.42 (0.91) 3.01 (0.94) 2.52 (0.88)
Triglycerides, mmol/l 1.68 (0.94) 1.62 (0.92) 1.30 (0.65) 1.37 (0.70)
Renal function
Creatinine, serum, μmol/l 93.4 (32.2) 80.0 (20.6) 81.3 (18.5) 83.3 (19.3)
ACR, mg/mmol 9.48 (37.4) 4.14 (16.5) 3.23 (22.7) 3.38 (15.3)
eGFR 60.8 (20.3) 71.3 (19.4) 69.6 (17.7) 66.9 (18.9)
Binary variables are reported as n(%) and quantitative data are reported as mean (SD)
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, HDL high-density lipoprotein, LDL low-density lipoprotein, ACR albumin creatinine
ratio, eGFR estimated glomerular filtration rate
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(RHI). Subjects with T2D had more severe carotid disease,
increased arterial stiffness, and impaired endothelial func-
tion while there was no difference in ABPI between sub-
jects with and without T2D (Table 4). Renin levels were
significantly associated with the severity of atherosclerosis
both in peripheral arteries and in the carotids. These asso-
ciations were similar in subjects with and without T2D.
Moreover, with the exception of the association between
renin and CCA IMT in the non-T2D group they remained
significant when adjusting for age, gender, total choles-
terol, HDL, smoking and importantly also for systolic
blood pressure (Table 5). There was a weak risk factor-
independent relationship between high renin levels and a
lower RHI among T2D subjects, but otherwise we found
no independent associations with arterial stiffness or
endothelial dysfunction (Table 5).
Influence of RAAS inhibition
In an additional approach to explore the role of RAAS
activation in vascular complications to T2D we analyzed
if ongoing treatment with RAAS inhibitors (e.g. ACE
inhibitors ARBs or renin inhibitors) was associated with
any difference in markers of atherosclerosis, arterial
stiffness and endothelial dysfunction. Subjects with or
without prevalent CVD were analyzed separately since
prevalent CVD has been shown to be associated with
more severe vascular pathologies [17]. Seventy-seven
percent of T2D subjects with prevalent CVD and 57 %
Fig. 1 Renin plasma levels in subjects with and without T2D and with and without CVD. Values are given as arbitrary units (linear scale). P-values
were calculated using the Mann-Whitney U test
Table 2 Odds-ratios for CVD risk with increased plasma renin levels (log2 scale)
Covariates All T2D Non-T2D
OR (95 % CI) p-value OR (95 % CI) p-value OR (95 % CI) p-value
Framingham (age, gender, total cholesterol, HDL, SBP, smoking) 1.37 (1.22–1.55) 9.5E-08 1.55 (1.34–1.80) 7.7E-09 1.45 (1.14–1.85) 3.0E-03
Framingham + eGFR 1.29 (1.14–1.45) 5.0E-05 1.42 (1.21–1.66) 1.2E-05 1.43 (1.12–1.83) 4.0E-03
Framingham + RAAS inhibitors 1.20 (1.06–1.36) 5.0E-03 1.41 (1.21–1.65) 1.3E-05 1.10 (0.84–1.44) ns
P-values from separate logistic regression models adjusted for the individual components of the Framingham risk score and study center, and in addition for eGFR
or RAAS inhibitors
SBP systolic blood pressure, HDL high-density lipoprotein, eGFR estimated glomerular filtration rate
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of the group with T2D subjects without prevalent CVD
received treatment with any type of RAAS-inhibitor.
Increased renin levels were observed in subjects treated
with RAAS-inhibitors both in the CVD (median (IQR)
355 (231–584) versus 224 (151–377) AU) and non-
CVD groups (271 (167–474) versus 167 (108–254)
AU). No significant differences in ABPI, carotid IMT,
carotid plaque area, PWV or RHI between T2D sub-
jects with or without RAAS inhibitors (data not
shown). In the non T2D subjects RAAS-inhibition was
associated with increased plaque area in the CVD
group and increased CCA IMT, carotid bulb IMT and
PWV in the non-CVD group (Table 6).
To explore the possibility that the renin associations
with CVD and atherosclerosis burden was explained by
a more frequent treatment with RAAS-inhibitors in
subjects with more advanced disease we next analyzed
subjects with and without RAAS-inhibitors separately.
Subjects treated with renin inhibitors (n = 68) were ex-
cluded from these analyses as these do not have the
same increasing effect on plasma renin as ACE inhibitors
and ARBs. Moreover, since only 41 subjects in the non-
CVD, non-T2D group were treated with ACE inhibitors
Table 3 Pearson Correlations between plasma renin levels and
factors related to CVD
T2D Non-T2D
r p r p
Age 0.16 (0.10–0.23) 4.2E-07 0.26 (0.18–0.34) 2.5E-09
BMI 0.08 (0.01–0.14) 1.6E-02 0.19 (0.10–0.27) 2.0E-05
HbA1c 0.20 (0.14–0.26) 7.4E-10 0.25 (0.16–0.33) 3.3E-08
Systolic BP −0.15 (−0.21–0.09) 4.0E-06 −0.04 (−0.13–0.05) ns
HDL chol −0.15 (−0.21–0.09) 4.8E-06 −0.21 (−0.29–0.12) 3.8E-06
LDL chol −0.20 (−0.27–0.14) 8.4E-10 −0.28 (−0.36–0.19) 1.2E-09
Triglycerides 0.12 (0.06–0.19) 1.8E-04 0.09 (0.00–0.18) 5.0E-02
eGFR −0.29 (−0.35–0.23) <1.0E-16 −0.24 (−0.32–0.16) 6.9E-08
Plasma IL6 0.28 (0.22–0.33) <1.0E-16 0.29 (0.21–0.37) 4.9E-11
BMI body mass index, SBP systolic blood pressure, HDL high-density lipoprotein,
LDL low-density lipoprotein, eGFR estimated glomerular filtration rate
Table 4 Differences in vascular changes between subjects with
and without T2D
T2D Non-T2D p-value
ABPI 1.16 (1.07, 1.25) 1.17 (1.08, 1.25) ns
ABPI (right) 1.16 (1.07, 1.25) 1.17 (1.09, 1.25) ns
ABPI (left) 1.16 (1.07, 1.25) 1.17 (1.08, 1.25) ns
CCA IMT 0.91 (0.80, 1.04) 0.85 (0.75, 0.99) 5.1E-06
CCA IMT (right) 0.89 (0.77, 1.03) 0.84 (0.74, 0.97) 4.9E-05
CCA IMT (left) 0.91 (0.78, 1.06) 0.86 (0.74, 1.02) 5.9E-05
Bulb IMT 1.11 (0.93, 1.42) 1.05 (0.90, 1.30) 1.0E-03
Bulb IMT (right) 1.08 (0.90, 1.41) 1.01 (0.87, 1.30) 1.6E-03
Bulb IMT (left) 1.09 (0.92, 1.37) 1.05 (0.89, 1.28) 0.01
Plaque area 17.0 (10.7, 26.1) 15.6 (10.4, 22.6) 0.01
PWV 10.9 (9.3, 13.2) 9.6 (8.3, 11.4) 2.0E-16
RHI 2.01 (1.72, 2.48) 2.31 (1.90, 2.74) 4.1E-11
For each group the median is provided with the interquartile range, p-values
from Mann-Whitney U-test
ns non significant, ABPI ankle brachial pressure index, CCA common carotid
artery, IMT intima media thickness, PWV pulse wave velocity, RHI reactive
hyperemia index
Table 5 Association between plasma renin levels and measures
of atherosclerosis burden, arterial stiffness and endothelial
function
T2D Non-T2D
ABPI r −0.19 −0.15
95 % CI (−0.26, −0.13) (−0.23, −0.06)
pCor 7.7E-09 0.001
r2 0.14 0.20
pReg 7.4E-09 0.006
CCA IMT r 0.15 0.19
95 % CI (0.08, 0.21) (0.10, 0.27)
pCor 1.2E-05 4.7E-05
r2 0.15 0.29
pReg 0.015 ns
Bulb IMT r 0.27 0.30
95 % CI (0.20, 0.33) (0.21, 0.38)
pCor 1.1E-14 1.8E-10
r2 0.22 0.28
pReg 8.7E-07 0.001
Plaque area r 0.25 0.27
95 % CI (0.18, 0.32) (0.17, 0.36)
pCor 6.4E-12 1.4E-07
r2 0.25 0.31
pReg 3.3E-09 3.70E-05
PWV r 0.08 0.18
95 % CI (0.01, 0.15) (0.09, 0.27)
pCor 0.029 1.2E-04
r2 0.33 0.36
pReg ns ns
RHI r −0.14 −0.14
95 % CI (−0.21, −0.08) (−0.23, −0.05)
pCor 1.8E-05 0.002
r2 0.08 0.15
pReg 0.025 ns
r Pearson correlation coefficient, 95 % CI 95 % confidence interval for r,
pCor p-value for correlation significance, r2 proportion of variation explained
by linear regression model adjusted for age, gender, total cholesterol,
HDL systolic blood pressure, smoking, and study center, pReg p-value for
significance of renin coefficient in this model; data of imaging variables has
been log2-transformed to resemble normal distribution, ABPI ankle brachial
pressure index, CCA common carotid artery, IMT intima media thickness,
PWV pulse wave velocity, RHI reactive hyperemia index
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and ARBs we restricted the analyses to the T2D group.
In T2D subjects treated with RAAS inhibitors those
with CVD (n = 313) had higher plasma renin than those
without CVD (n = 256; 355 (231–584) versus 271 AU
(167–465), p = 9.2E-06). Also in T2D subjects without
RAAS inhibition higher renin levels was observed in
the CVD group (n = 150) than in the non-CVD group
(n = 211; 224 (151–377) versus 167 AU (108–253), p =
3.3E-05). The odds-ratio for CVD risk with increased
plasma renin levels was 1.45 (95 % C.I. 1.19–1.76) for
T2D subjects treated with RAAS inhibitors and 1.41
(95 % C.I. 1.04–1.93) for those not treated with RAAS
inhibitors when controlling for age, gender, total choles-
terol, HDL, systolic blood pressure, smoking and study
center. The pattern of renin associations with measures of
atherosclerosis burden, arterial stiffness and endothelial
function were also similar in T2D subjects with or without
treatment with RAAS inhibitors (Table 7). Taken together,
these observations demonstrate that the renin associations
with CVD and atherosclerosis burden observed in the
present study is not due a more frequent treatment with
RAAS-inhibitors in subjects with more advanced disease.
Plasma renin levels and atherosclerotic plaque structure
Since previous experimental data have shown that RAAS
activation can stimulate inflammation, expression of fibrous
proteins and smooth muscle cell growth we investigated if
plasma levels of renin were related to atherosclerotic plaque
content of these factors in a cohort of 205 carotid endarter-
ectomy patients. The clinical characteristics of this cohort
have been reported previously [19]. Weak but statistically
significant associations were found between plasma renin
levels and the plaque content of platelet-derived growth
factor (r= 0.14, p < 0.05) and TNF-α (r =−0.16, p < 0.05),
but there were no significant associations with plaque
content of collagen, elastin, IL-6, monocyte chemotactic
protein-1, vascular endothelial growth factor or immuno-
staining for macrophages or smooth muscle cells (data
not shown). Renin levels in plaque homogenates were
analyzed using the Proximity Extension Assay. There was
a strong correlation between the levels of renin in plasma
and atherosclerotic plaque tissue (r = 0.80, p = 1.0E-40).
However, with the exception of a trend for a correlation
with the plaque content of platelet-derived growth factor
(r = 0.13, p = 0.07) there were correlations between the
plaque renin content and other plaque components.
Table 6 Differences in vascular changes in non-T2D subjects without or without treatment with any type of RAAS inhibitor
No T2D with CVD No T2D without CVD
Variable Yes No MedianYes MedianNo p-value Yes No MedianYes MedianNo p-value
ABPI 146 76 1.16 (1.08–1.25) 1.13 (1.02–1.23) ns 49 196 1.17 (1.12–1.23) 1.17 (1.10–1.25) ns
CCA IMT (mm) 147 73 0.88 (0.78–1.04) 0.88 (0.78–0.99) ns 48 192 0.92 (0.82–1.03) 0.81 (0.72–0.96) 7.4E-04
Bulb IMT (mm) 132 66 1.20 (0.98–1.44) 1.07 (0.96–1.31) ns 47 187 1.15 (0.99–1.38) 0.96 (0.84–1.15) 1.9E-04
Plaque area (mm2) 128 67 18.5 (12.5–24.6) 13.58 (10.9–18.7) 0.004 40 134 15.8 (10.7–29.8) 13.2 (7.8–20.0) ns
PWV (m/sec) 135 63 10.2 (8.3–11.8) 9.7 (8.5–11.8) ns 46 189 9.8 (9.0–11.0) 9.2 (7.9–10.7) 0.025
RHI 158 77 2.2 (1.8–2.6) 2.3 (1.9–2.7) ns 50 196 2.25 (1.88–2.48) 2.41 (2.00–2.81) ns
Difference of imaging marker was assessed by Mann-Whitney U-test, medians are presented together with IQRs
ns not significant, ABPI ankle brachial pressure index, CCA common carotid artery, IMT intima media thickness, PWV pulse wave velocity, RHI reactive hyperemia index
Table 7 Associations between renin levels and measures of
atherosclerosis burden, arterial stiffness and endothelial function
T2D
RAASi NoRAASi
ABPI r −0.19 −0.09
pCor 1.6E-05 ns
r2 0.14 0.16
pReg 3.6E-04 ns
CCA IMT r 0.14 0.13
pCor 7.9E-04 0.021
r2 0.15 0.20
pReg 0.007 ns
Bulb IMT r 0.26 0.29
pCor 1.0E-08 9.40E-07
r2 0.20 0.3
pReg 3.3E-05 0.029
Plaque area r 0.26 0.20
pCor 7.7E-09 0.002
r2 0.26 0.29
pReg 3.2E-08 ns
PWV r 0.02 0.09
pCor ns ns
r2 0.31 0.38
pReg ns ns
RHI r −0.16 −0.15
pCor 2.3E-04 0.007
r2 0.09 0.11
pReg 0.036 ns
r is Pearson correlation coefficient, and r2 is proportion of variation explained
by a linear regression model adjusted for age, gender, total cholesterol
HDL systolic BP, smoking, eGFR, IL6, and study center
RAASi RAAS inhibitor treatment
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Discussion
There is evidence from clinical trials that treatment with
RAAS inhibitors slows the onset of T2D and reduces the
risk of renal complications in manifest T2D [20]. More-
over, experimental studies have shown that activation of
RAAS stimulates processes known to be of importance
for development of atherosclerosis including inflamma-
tion, oxidative stress, smooth muscle cell growth and
fibrosis suggesting that it could play an important role
also in the macrovascular complications associated with
T2D [21]. The concept that RAAS promotes atherogen-
esis in diabetes has gained support from a few animal
studies [11, 12], but evidence from randomized clinical
trials of RAAS inhibitors with cardiovascular end points
has been inconsistent [22]. Thus, the clinical importance
of RAAS activation in the development of cardiovascular
complications in T2D remains to be fully established. In
the present study we investigated if RAAS activation, as
assessed by circulating renin levels, was associated with
the severity of vascular complications in T2D subjects
with and without prevalent CVD. Our findings show that
there is a significant association between circulating renin
levels and atherosclerotic burden in the carotid and per-
ipheral arteries in subjects with T2D and that these as-
sociations are independent of systolic blood pressure
and other major cardiovascular risk factors. In accord-
ance, T2D subjects with clinically manifest CVD were
characterized by increased renin levels and this difference
remained significant when adjusting for renal function,
treatment with RAAS-inhibitors and cardiovascular risk
factors including systolic blood pressure. Collectively these
observations are well in line with the proposed role for
RAAS activation in cardiovascular complications in T2D.
Notably, plasma renin levels were elevated also in non-
T2D subjects with prevalent CVD and demonstrated sig-
nificant associations with markers of atherosclerosis also
in this group. Moreover, renin levels were found to link
with factors characteristic for T2D, such as HBA1c, BMI
and low HDL, also among subjects without T2D. How-
ever, renin levels were lower in subjects without T2D and
the vascular changes were less pronounced. These obser-
vations are in line with previous findings that insulin
resistance stimulates the expression of renin and that this
may contribute to a more severe progression of athero-
sclerosis in T2D [1, 2, 5].
In spite of the association between renin and markers
of atherosclerotic burden we found no evidence for re-
duced atherosclerosis in subjects treated with RAAS-
inhibitors. There are several possible explanations to this
finding. First, it cannot be excluded that RAAS activa-
tion has no direct effect on atherosclerosis development
in humans and that the association between renin and
disease severity observed here is caused by association of
renin with another atherogenic factor. However, the fact
that renin remained significantly associated to atheroscler-
otic burden when adjusting for other cardiovascular risk
factors, as well as renal function argues against this. Sec-
ond, it could be that vascular changes caused by increased
RAAS activation over many years are not easily reversible
by providing RAAS inhibition in different time-frames.
Third, it is possible that RAAS inhibition when given
alone may be sufficient to reduce or inhibit the progres-
sion of disease but when co-administered with other
potent anti-atherogenic drugs, such as statins, the effect of
RAAS inhibition may become too small to be of clinical
significance. In line with the latter possibility treatment
with ACE-inhibition reduced myocardial events in the
HOPE study in which only about 20 % received lipid-
lowering therapy [14] while no significant effect of ACE-
inhibition on major coronary events could be observed
in the ADVANCE trial in which about 50 % received
lipid-lowering therapy [23]. Unexpectedly, RAAS-inhibition
was associated with more severe carotid atherosclerosis in
non-T2D subjects. The reason for this association remains
to be elucidated but it does not support the existence of an
anti-atherogenic effect of RAAS inhibitors.
Experimental studies have shown that angiotensin II
induces vascular oxidative stress leading to decreased
endothelial relaxation and endothelial dysfunction [24]. In
accordance with these findings we observed an inverse
correlation between plasma renin and the RHI in the
present study. However, no differences were observed in
RHI between subjects with or without RAAS-inhibition.
Angiotensin II has also been shown to affect processes
involved in atherosclerotic plaque development and sta-
bility. Increased expression of adhesion molecules and
pro-inflammatory cytokines including monocyte chemo-
tactic protein-1 and IL-6 has been reported in monocytes,
smooth muscle cells and endothelial cells exposed to
angiotensin II [25–28]. Additionally, angiotensin II has
been shown to stimulate smooth muscle cell growth and
collagen production [10, 29, 30]. In the present study we
found no or only weak associations between plasma renin
and the expression of pro-inflammatory cytokines, fi-
brous proteins and smooth muscle cells in atherosclerotic
plaques obtained from carotid endarterectomy patients.
Taken together these findings suggest that RAAS activa-
tion does not significantly affect plaque composition and
vulnerability. However, since the experimental data show
that angiotensin II stimulates both inflammatory and
repair processes it is possible that it may contribute to
plaque development without affecting the balance be-
tween individual plaque components. It is also possible
that local RAAS activation is of more importance for these
processes than systemic RAAS activation.
There are some limitations of the present study that
should be considered. Most importantly, the observa-
tional design of the study does not allow for conclusions
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regarding cause and effect relations. Thus, our findings
do not provide clinical evidence for an atherogenic role
of renin and RAAS activation. They are, however, well in
line with experimental data suggesting that RAAS acti-
vation exuberate several biological processes involved in
plaque development. The finding that treatment with
RAAS-inhibitors does not affect atherosclerosis severity
also needs to be interpreted with caution since this is an
observational study and information regarding length of
treatment is unfortunately lacking. Another important
limitation is that RAAS activation was only assessed
indirectly through analysis of renin levels.
Conclusions
Our findings provide clinical evidence for an association
between RAAS activation and atherosclerotic burden
both in subjects with and without T2D. Plasma renin
and atherosclerosis are concomitantly increased in sub-
jects with T2D as compared to age and sex-matched sub-
jects without T2D suggesting that these associations may
be of particular importance in vascular complication of
diabetes. Importantly, the association between renin and
atherosclerotic burden was independent of blood pressure
and other major cardiovascular risk factors suggesting
involvement of a direct effect of RAAS activation on the
vascular wall. However, our findings also suggest that
treatment with RAAS inhibitors may have limited effect-
iveness in counteracting the atherogenic effects of RAAS
activation.
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